Aimovig
erenumab
Table of contents
Overview
Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.
Aimovig contains the active substance erenumab.
-
List item
Aimovig : EPAR - Summary for the public (PDF/72.56 KB)
First published: 08/08/2018
Last updated: 06/05/2019 -
-
List item
Aimovig : EPAR - Risk-management-plan summary (PDF/127.6 KB)
First published: 08/08/2018
Last updated: 02/03/2023
Authorisation details
Product details | |
---|---|
Name |
Aimovig
|
Agency product number |
EMEA/H/C/004447
|
Active substance |
erenumab
|
International non-proprietary name (INN) or common name |
erenumab
|
Therapeutic area (MeSH) |
Migraine Disorders
|
Anatomical therapeutic chemical (ATC) code |
N02CD01
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Novartis Europharm Limited
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
26/07/2018
|
Contact address |
Vista Building |
Product information
20/02/2023 Aimovig - EMEA/H/C/004447 - R/0024
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Analgesics
Therapeutic indication
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.